Clinical Trial Update: Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan [Phase 3]

View source ↗

Summary

This Phase 3 trial update examines whether irbesartan can preserve residual renal function in adults with chronic kidney disease on haemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Irbesartan (irbesartan)

Snippet

Sponsor: University of Aarhus | Conditions: Kidney Failure, Chronic | Phase 3 | Status: COMPLETED